CITATION REPORT List of articles citing

Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis

DOI: 10.1007/s40265-018-0992-5 Drugs, 2018, 78, 1791-1804.

Source: https://exaly.com/paper-pdf/70447655/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
136	Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. <i>Drugs</i> , 2019 , 79, 1435-1454	12.1	55
135	An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome. 2019 , 20, 1563-1574		1
134	Use of complementary and alternative medicine among adults with epilepsy in a university epilepsy clinic in Poland. 2019 , 98, 40-44		2
133	Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study. 2019 , 10, 716		28
132	Cannabidiol as a potential treatment for psychosis. 2019 , 9, 2045125319881916		45
131	[Cannabis and cannabinoids-easier access, hype and disappointment: What has been confirmed in therapy?]. 2019 , 60, 309-314		0
130	Cannabis Use Disorder and Epilepsy: A Cross-National Analysis of 657 072 Hospitalized Patients. 2019 , 28, 353-360		5
129	Drug-drug interactions between antiepileptics and cannabinoids. 2019 , 15, 407-415		8
128	Efficacy and safety of Levetiracetam as adjunctive treatment in children with focal onset seizures: A systematic review and meta-analysis. 2019 , 153, 40-48		8
127	Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety. <i>Drugs</i> , 2019 , 79, 417-431	12.1	46
126	The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery. 2019 , 14, 195-197		11
125	Cannabis Use in Adolescence: A Review of Neuroimaging Findings. 2020 , 16, 83-105		16
124	Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. 2020 , 102, 106635		13
123	Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam. 2020 , 160, 106263		14
122	The Use of Cannabis as a Treatment for Epilepsy in Adult Patients: Are Side Effects a Limitation of Use?. 2020 , 37, 9-14		1
121	Cannabis for Pediatric Epilepsy. 2020 , 37, 2-8		12
120	Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals. 2020 , 177, 12	27-124	092

(2020-2020)

119	A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?. 2020 , 170, 107861	9
118	Cannabinoids for drug-resistant seizures in a critically ill patient-Case report and literature review. 2020 , 45, 570-572	
117	The neuropharmacology of cannabinoid receptor ligands in central signaling pathways. 2020,	7
116	A Survey on Cannabinoid Treatment of Pediatric Epilepsy Among Neuropediatricians in Scandinavia and Germany. 2020 , 8, 416	O
115	The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol. 2020 , 35, e2749	6
114	Application of Cannabinoids in Neurosciences: Considerations and Implications. 2020 , 43, 216-231	
113	Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis. 2020 , 34, 1105-1120	17
112	Cannabidiol Treatment for Refractory Epilepsies in Pediatrics. 2020 , 11, 586110	7
111	Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. 2020 , 54, 1109-1143	15
110	Is cannabidiol hepatotoxic or hepatoprotective: A review. 2020 , 4, 239784732092294	Ο
109	Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. 2020 , 61, 1090-1098	35
108	Herb-drug interaction of gastrodiae rhizoma on carbamazepine: A pharmacokinetic study in rats. 2020 , 165, 106376	1
107	Zur klinischen Wirksamkeit von Prparaten aus dem Hanf. 2020 , 41, 182-187	
106	Effectiveness of cannabidiol in a prospective cohort of children with drug-resistant epileptic encephalopathy in Argentina. 2020 , 80, 75-80	4
105	Considerations and Implications of Cannabidiol Use During Pregnancy. 2020 , 24, 38	13
104	Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part II. 2020 , 21, 15	1
103	Efficacy of cannabinoids for treating paediatric spasticity in cerebral palsy or traumatic brain injury: what is the evidence?. 2020 , 62, 1007	O
102	-Related Severe Epileptic Encephalopathy Treated with Memantine: An Example of Precision Medicine. 2020 , 9, 252-257	6

101	Use of cannabidiol (CBD) for the treatment of chronic pain. 2020 , 34, 463-477	16
100	Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects. 2020 , 16, 381-396	28
99	Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety. 2020 , 34, 229-241	37
98	Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. 2020 , 104, 106939	28
97	Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence. 2020 , 5, 191-196	14
96	Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. 2020 , 16, 517-526	25
95	Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. 2020 , 45, 1799-1806	74
94	Cellular-Scale Microelectrode Arrays to Monitor Movement-Related Neuron Activities in the Epileptic Hippocampus of Awake Mice. 2021 , 68, 19-25	3
93	Medicinal applications of cannabis/cannabinoids. 2021 , 38, 1-10	6
92	Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. 2021 , 21, 99-110	11
91	Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders?. 2021 , 6, 7-18	10
90	Cannabinoids: A New Perspective on Epileptogenesis and Seizure Treatment in Early Life in Basic and Clinical Studies. 2020 , 14, 610484	2
89	Age-dependent anticonvulsant actions of perampanel and brivaracetam in the methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) model of seizures in developing rats. 2021 , 73, 296-302	0
88	A validated method for the simultaneous quantification of cannabidiol, Itetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trial. 2021 , 13, 614-627	4
87	Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician. 2021 , 10, 1-5	
86	Carbonyl Compounds in Mainstream Smoke of Hemp Cigarettes. 2021 , 6, 349-357	
85	A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. 2021 , 4, 21-42	5
84	: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC. 2021 , 9,	7

(2021-2021)

83	Functional Connectivity Derived From Electroencephalogram in Pharmacoresistant Epileptic Encephalopathy Using Cannabidiol as Adjunctive Antiepileptic Therapy. 2021 , 15, 604207	0
82	Analgesic and Anti-Inflammatory Effects of Perampanel in Acute and Chronic Pain Models in Mice: Interaction With the Cannabinergic System. 2020 , 11, 620221	2
81	From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?. 2021 , 12, 638032	3
80	Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders. 2020 , 11, 618065	5
79	Specialty seeds: Nutrients, bioactives, bioavailability, and health benefits: A comprehensive review. 2021 , 20, 2382-2427	9
78	Cannabidiol Does Not Impair Anabolic Signaling Following Eccentric Contractions in Rats. 2021 , 31, 93-100	2
77	Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. 2021 , 185, 108442	18
76	Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. 2021 , 35, 265-281	7
75	Kratom: The safe legal high?. 2021 , 117, 107882	2
74	Cannabinoids in Neurology - Position paper from Scientific Departments from Brazilian Academy of Neurology. 2021 , 79, 354-369	3
73	Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. 2021 , 117, 107862	7
72	What are the informational pathways that shape people's use of cannabidiol for medical purposes?. 2021 , 3, 13	4
71	Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. 2021 , 12, 673135	5
70	Endocannabinoid System and Its Regulation by Polyunsaturated Fatty Acids and Full Spectrum Hemp Oils. 2021 , 22,	5
69	Much Ado about Dosing: The Needs and Challenges of Defining a Standardized Cannabis Unit 2021 , 4, 121-124	3
68	Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. 2021 , 3, 22	13
67	Chinese Herbal Medicine for Treating Epilepsy. 2021 , 15, 682821	2
66	Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. 2021 , 46, 2101-2111	1

65	The Phytochemical Diversity of Commercial Cannabis in the United States.	3
64	Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. 2021 , 38, 887-910	1
63	The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. 2021, 22,	14
62	Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon. 2021 ,	1
61	Cannabidiol (CBD) and cognition in epilepsy. 2021 , 124, 108316	3
60	Drugs for patients with epilepsy and excessive daytime sleepiness. 2021 , 124, 108311	O
59	Clinical Impact: Safety and Efficacy of Cannabidiol IBDIPredicated on UsersiQuality-of-Life Assessments in Southern Nigeria. 2021 , 11, 21-28	
58	Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review. 2021 , 1264, 29-45	22
57	Meet Your Stress Management Professionals: The Endocannabinoids. 2020 , 26, 953-968	9
56	Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and	• •
30	Recommendations for Future Research. 2020 , 6, 27	20
55	Recommendations for Future Research. 2020 , 6, 27 Cannabidiol Adverse Effects and Toxicity. 2019 , 17, 974-989	121
55	Cannabidiol Adverse Effects and Toxicity. 2019 , 17, 974-989 A Volumetric Absorptive Microsampling Technique to Monitor Cannabidiol Levels in Epilepsy	121
55 54	Cannabidiol Adverse Effects and Toxicity. 2019 , 17, 974-989 A Volumetric Absorptive Microsampling Technique to Monitor Cannabidiol Levels in Epilepsy Patients. 2020 , 11, 582286	121
55 54 53	Cannabidiol Adverse Effects and Toxicity. 2019, 17, 974-989 A Volumetric Absorptive Microsampling Technique to Monitor Cannabidiol Levels in Epilepsy Patients. 2020, 11, 582286 Medical Cannabis in Children. 2020, 11,	121 2 5
55 54 53 52	Cannabidiol Adverse Effects and Toxicity. 2019, 17, 974-989 A Volumetric Absorptive Microsampling Technique to Monitor Cannabidiol Levels in Epilepsy Patients. 2020, 11, 582286 Medical Cannabis in Children. 2020, 11, Cannabis, More Than the Euphoria: Its Therapeutic Use in Drug-Resistant Epilepsy. 2020, 12, e9299 Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West	121 2 5
55 54 53 52 51	Cannabidiol Adverse Effects and Toxicity. 2019, 17, 974-989 A Volumetric Absorptive Microsampling Technique to Monitor Cannabidiol Levels in Epilepsy Patients. 2020, 11, 582286 Medical Cannabis in Children. 2020, 11, Cannabis, More Than the Euphoria: Its Therapeutic Use in Drug-Resistant Epilepsy. 2020, 12, e9299 Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients. 2021, 92, 238-243 Establishing Credibility for Medical Marijuana: The Proposed Prometheus Dispensary Registry for	121 2 5

(2020-2020)

47 Medicinal Applications of Cannabidiol from the Genus Cannabis L.. **2020**, 201-241

46	Cannabidiol Oral Solution 🖟 New Class of Antiseizure Medication. 2020 , 15, 19	1
45	Optimization of the Heterologous Expression of the Cannabinoid Type-1 (CB) Receptor. 2021 , 12, 740913	O
44	Patterns and correlates of cannabidiol product and marijuana co-use in a sample of U.S. young adults. 2021 , 126, 107185	О
43	The use of medical cannabis in pediatric palliative care: a case series. 2021 , 47, 229	O
42	Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews. 2021 ,	3
41	Cannabidiol Does Not Impact Acute Anabolic or Inflammatory Signaling in Skeletal Muscle. 2021,	1
40	In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. 2021 , 159, 112722	1
39	Channelopathy of Dravet Syndrome and Potential Neuroprotective Effects of Cannabidiol 2021 , 13, 11795735211048045	O
38	Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy 2022 , 95, 56-63	1
37	Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis. 2021 , 11, 23462	1
36	Approach to the Medical Treatment of Epilepsy <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022 , 28, 483-499	
35	Data_Sheet_1.docx. 2019 ,	
34	Image_1.tiff. 2019 ,	
33	lmage_2.tiff. 2019 ,	
32	Table_1.pdf. 2019 ,	
31	Table_2.pdf. 2019 ,	
30	Data_Sheet_1.PDF. 2020 ,	

29	The phytochemical diversity of commercial Cannabis in the United States PLoS ONE, 2022, 17, e026749	8 .7	2
28	Pharmaceutical Applications of Hemp. 2022 , 97-133		
27	Cannabidiol (CBD) in children with drug-resistant epilepsy: An initial experience from a developing country. <i>Journal of Pediatric Neurosciences</i> , 2022 ,	0.5	
26	Cannabisgebrauch bei Jugendlichen.		
25	Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders. 2022 , 27, 4961		2
24	Cannabis-based medicinal products: a clinical guide. 2022 , 18, 170-174		
23	Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis. 13,		1
22	Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety. 13,		O
21	Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.		3
20	Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. 2022 , 114238		2
19	Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. 2022 , 114237		1
18	The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials.		O
17	Updates on Sturge-Weber Syndrome.		O
16	Cannabidiol inhibits microglia activation and mitigates neuronal damage induced by kainate in an in-vitro seizure model. 2022 , 174, 105895		1
15	Phytocannabinoids, the Endocannabinoid System and Male Reproduction. 2023, 41, 1		O
14	The effects of cannabidiol on the driving performance of healthy adults: a pilot randomized clinical trial. 2022 , 100053		1
13	A Retrospective Study of the Profile and Outcome of Children with Dravet Syndrome in a Tertiary Care Hospital of Southern India.		O
12	Clinical Outcome Data of Children Treated with Cannabis Based Medicinal Products for Treatment Resistant Epilepsy [Analysis from the UK Medical Cannabis Registry.		1

CITATION REPORT

11	Common practical questions and answers at the British Association for Psychopharmacology child and adolescent psychopharmacology course. 026988112211400	О
10	Small molecules in the treatment of COVID-19. 2022 , 7,	3
9	Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders. 2023, 15, 204	1
8	Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies. 2023 , 16, 155	О
7	The Functional Compounds of Cannabis sativa. 2023,	О
6	The safety and relative effectiveness of non-psychoactive cannabinoid formulations for the improvement of sleep: a double-blinded, randomized controlled trial.	O
5	Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids. 2023 , 37, 1526-1538	О
4	Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications. 2023,	O
3	Cannabidiol-Loaded Nanocarriers and Their Therapeutic Applications. 2023, 16, 487	О
2	Letter to the Editor: Second-line cannabis therapy in patients with epilepsy. 2023 , 107731	O
1	Adverse Events of Cannabidiol Use in Patients With Epilepsy. 2023 , 6, e239126	О